LRRC46: A Potential Drug Target Or Biomarker (G90506)

Target Name: LRRC46

NCBI ID: G90506

LRRC46

Other Name(s): LRC46_HUMAN | leucine rich repeat containing 46 | Leucine rich repeat containing 46 | Leucine-rich repeat-containing protein 46

LRRC46: A Potential Drug Target Or Biomarker

LRRC46 (Long non-coding RNA gene LRRC46) is a gene that has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LRRC46 is a long non-coding RNA gene that has been shown to play a role in regulating various cellular processes, including cell adhesion, migration, and survival.

The LRRC46 gene has been shown to have various functions in different organisms, including humans. LRRC46 has been shown to be involved in the regulation of cell adhesion and migration, which are important processes that are critical for the development and progression of various diseases.

One of the most promising aspects of LRRC46 is its potential as a drug target. LRRC46 has been shown to play a role in the regulation of cancer cell growth and survival, which makes it an attractive target for cancer therapies. LRRC46 has also been shown to be involved in the regulation of neurodegenerative diseases, which makes it a potential target for therapies that are aimed at treating these conditions.

LRRC46 has also been shown to be involved in the regulation of autoimmune disorders, which are a group of conditions that cause the immune system to react against the body's own tissues or organs. LRRC46 has been shown to play a role in the regulation of immune cell function and has been shown to be involved in the development of autoimmune disorders.

In addition to its potential as a drug target, LRRC46 has also been shown to have potential as a biomarker. LRRC46 has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. This makes it a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LRRC46 has also been shown to be involved in the regulation of stem cell proliferation and differentiation. This is important because stem cells are a promising source of cancer therapies. LRRC46 has been shown to play a role in the regulation of stem cell proliferation and differentiation, which makes it a potential target for therapies aimed at treating cancer.

LRRC46 has also been shown to be involved in the regulation of tissue repair and regeneration. This is important because repair and regeneration are critical processes that are involved in the healing of injuries and diseases. LRRC46 has been shown to play a role in the regulation of tissue repair and regeneration, which makes it a potential target for therapies aimed at treating injuries and diseases.

In conclusion, LRRC46 is a gene that has been shown to play a role in various cellular processes and has been identified as a potential drug target or biomarker in a variety of diseases. Further research is needed to fully understand the functions of LRRC46 and its potential as a drug or biomarker.

Protein Name: Leucine Rich Repeat Containing 46

The "LRRC46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets